Latest Interviews
Showing 16–17 of 17 transcripts.
Clear all filters- Goldman Sachs1h 2m
An Update on Therapies and Vaccines
Sharmin Mossavar-Rahmani, Dr. Richard Hatchett, Esther Krofah, Dr. Paul Stoffels
On April 14, 2020, Goldman Sachs CIO Wealth Management hosted Sharmin Mosavar-Rahmani for the eighth iteration of a COVID-19 series discussing the epidemiological landscape of nearly 2 million infections and 110,000 fatalities. Experts outlined a pipeline where effective therapies are expected within four to six months while vaccines leveraging platforms from CEPI and Johnson & Johnson may require 12 to 18 months, with potential emergency use by the first quarter of 2021. The call further detailed critical challenges regarding antibody test accuracy, the certainty of a second wave, and the necessity for aggressive surveillance and testing infrastructure to facilitate any safe economic reopening.
- Milken Institute56 min
Superbugs: Avoiding an Existential Threat to Humanity
Esther Krofah, Valeria Bortolaia, Ron Daniels, Peter Jackson, Peter Piot, Lance Price, Sneha Kemka
This analysis details the critical global escalation of antimicrobial resistance, which currently causes 700,000 annual deaths and threatens to reach 10 million by 2050 without urgent intervention. The event highlights a pharmaceutical market failure where major drug withdrawals have shifted innovation to undercapitalized SMEs, necessitating new economic incentives like the UK's pilot pull mechanism to fund R&D. Strategic solutions prioritize infection control, agricultural bans on growth promoters, and precision diagnostics to bridge the gap between scientific discovery and clinical application.